From envisioning (1st photo), via preparing (2nd photo) to achieving (last photo): Uromigos cup on top of Mount Rainier! Looking forward to next meeting in Nashville Sept 27-28! Brian Rini, MD Tom Powles Sumanta K. Pal, MD, FASCO Tanya Dorff Shilpa Gupta Julie Gralow Rahul Banerjee, MD, FACP Jessica Hawley MD MS

Great start to World GU Conference with an interactive poster session. Hannah Dzimitrowicz McManus discussing high uptake of combined therapy for mHSPC in IRONMAN Registry Lorelei Mucci

Lots of ongoing questions for PSMA PET from Dana Rathkopf Uromigos — XRT to PSMA avid lesions vs primary? We have data UTSW Simmons Cancer Center suggesting time to castration resistance is long & this is early met disease — should not skip definitive treatments. World GU Conference #WorldGU24

Fun session and our community oncology panel was AMAZING. Thanks to Uramiga Dana Rathkopf for leading the prostate cancer portion.

New article in press: Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 8-year follow-up results of efficacy and safety from the phase III CheckMate 214 trial. Toni Choueiri, MD Brian Rini, MD Robert Motzer MD

Ahead of SUNNIFORECAST results, do you use Ipi/Nivo for Non-clear cell RCC? pubmed.ncbi.nlm.nih.gov/35210307/ults

The Cancer Immunity Cycle has been updated! Listen to the details here as Ira Mellman breaks down this update. spotifyanchor-web.app.link/e/U3CbGVSIbMb

1/ Results from #LITESPARK-005 are out NEJM! The phase 3 trial that led to HIF-2 inhibitor Belzutifan (BEL) U.S. FDA approval Dec 2023 in pretreated pts w/ #ccRCC. Presentation #ESMO24 @myEsmo Check it out: nejm.org/doi/full/10.10…

In participants with advanced renal-cell carcinoma, belzutifan, a HIF-2α inhibitor, was superior to everolimus, an mTOR inhibitor, with respect to progression-free survival and tumor response. Read the full LITESPARK-005 trial results: nej.md/4cvmO2R

Belzutifan significantly outperformed everolimus in heavily pretreated clear cell renal cancer. Toni Choueiri, MD Brian Rini, MD Laurence Albiges ⬆️ RR, PFS, QOL but no OS. Data suggests belzutifan is better in less heavily treated disease and in combination. 1st line and adjuvant trials awaited

Can’t wait for amazing Uromigos meeting! I mailed the trophy back to Brian Rini, MD and look forward to #Uromigoscup Tanya Dorff Shilpa Gupta Matt Galsky Karine Tawagi MD Toni Choueiri, MD Hans Hammers Tian Zhang, MD, MHS Laurence Albiges Michael Morris MashupMD Amanda Nizam, MD Fred Hutchinson Cancer Center Bladder Cancer Advocacy Network

⚡️What happens when “pastamigos” meet Uromigos 😃 Served with love 🍝🍽️ 🎧 Petros Grivas Brian Rini, MD Tom Powles

The EMA has approved Enfortumab Vedotin and pembrolizumab for 1st line urothelial cancer. It supersedes 1st platinum based therapy as the new standard of care in Europe. astellas.com/en/news/29371?…

Uromigos We are looking forward to the Uromigos Annual meeting in Nashville 27-29th September! Here is our entry from Barts Experimental Cancer Medicine Centre to win the ⭐️golden ticket🤞🤞🤞 Tom Powles Brian Rini, MD Tres Uramigas

New article in press: The ESMO Tumour-Agnostic Classifier and Screener (ETAC-S): a tool for assessing tumour-agnostic potential of molecularly guided therapies and for steering drug development. Ben Westphalen FabriceAndre Vivek Subbiah, MD

Now that EV+pembro is approved by FDA & EMA, we need to build this knowledge before prematurely defining strict criteria.

Should Enfortumab Vedotin with Pembrolizumab be avoided due to baseline clinical conditions? Sometimes, but clinical judgement is more important than predefined criteria Andrea Apolo, M.D. Shilpa Gupta joaquim bellmunt Jonathan Rosenberg MD Michiel van der Heijden & Lisa Cordes gbr01.safelinks.protection.outlook.com/?url=https%3A%…

We have a @uromigos Nashville 24 golden ticket 🎫 winner Dimitra Bakaloudi MD, MS for 27th and 28th Sept 👏👏☀️☀️. Session include MIBC, new ADCs, papillary RCC, cellular therapies and the Uromigos cup with 🇯🇵 and Tres Uramigas 🇺🇸 🇪🇸 🇲🇽 teams . New trial designs and defining oligomet RCC…

urothelial cancer highlight #ESMO24 New ADC data (1st line DV/pembo, EGFR/HER3),TAR200 (pretzel) in MIBC (SUNRISE4), EV/pembro biomarkers (EV302), adjuvant (TOMBOLA) and neoadjuvant (VOLGA) ctDNA, updates on adjuvant pembro (AMBASSADOR), neoadjuvant chemo +/- durvalumab (NIAGRA)

Thank you TIME for highlighting our work in Kidney Cancer at Dana-Farber and Dana-Farber Lank Center for Genitourinary Oncology time.com/7018184/kidney…